Daniel Jones

Daniel Jones's recent work focuses on blood cancers (leukemias and lymphomas) and the safety of drugs called Bruton tyrosine kinase (BTK) inhibitors, which are used to treat these diseases. Much of this work involves meta-analyses—studies that combine data from multiple clinical trials—to assess side effects such as heart problems, bleeding, high blood pressure, and secondary cancers linked to these drugs. Earlier and unrelated publications touch on bone/joint cell biology and a medical diagnostic AI tool, suggesting a broader but less consistent body of work outside the main leukemia/BTK inhibitor focus.

Publication output has been irregular over the last decade, with gaps in some years (e.g., 2018, 2023) and a recent increase in 2025, averaging about 2 publications per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026